38
Participants
Start Date
August 31, 2024
Primary Completion Date
August 31, 2026
Study Completion Date
August 31, 2026
S095029
Participants will be treated with S095029 via intravenous (IV) infusion every 3 weeks (Q3W).
pembrolizumab 200 mg (KEYTRUDA ®)
Participants will be treated with 200 mg of pembrolizumab via intravenous (IV) infusion every 3 weeks (Q3W).
Rigshospitalet, Copenhagen
UZ Leuven Campus Gasthuisberg, Leuven
Bugat Pal Hospital, Gyöngyös
Chu de Liege, Liège
Odense Universitetshospital, Odense
The Queen Elizabeth Hospital, Woodville South
Landeskrankenhaus (SALK), Salzburg
Fondazione IRCCS Istituto Nazionale dei Tumor, Milan
Centre Georges Francois Leclerc, Dijon
Hospital Universitario Gregorio Marañón, Madrid
Institut Bergonié, Bordeaux
Ocala Oncology Center Pl, Ocala
Policlinico G.B. Rossi A.O.U.I. Di Verona, Verona
Hospital Universitario Marqués de Valdecilla, Santander
Inst. de Cancer de L'ouest, Saint-Herblain
Hospital Universitario de Valencia, Valencia
Investigative Clinical Research of Indiana, Llc, Noblesville
Institut de Cancerologie de Lorraine, Vandœuvre-lès-Nancy
A.O.U. Pisana-Ospedale Santa Chiara, Pisa
Chru Lille - Hopital Claude Huriez, Lille
MD Anderson Cancer Center, Houston
A.O.U. Seconda Università Degli Studi Di Napoli, Campania
Institut Curie, Saint-Cloud
Beijing Cancer Hospital, Beijing
Liaoning Cancer Hospital, Shenyang
Harbin Medical University Cancer Hospital, Harbin
Fudan University Shanghai Cancer Center, Shanghai
Shandong Cancer Hospital Institute, Jinan
Sir Run Run Shaw Hospital Zhejiang University School of Medicine Qingchun Branch, Hangzhou
Henan Cancer Hospital, Zhengzhou
Cancer Institute Hospital of Jfcr, Koto-Ku
Osaka International Cancer Institute, Osaka
Ordensklinikum Linz, Linz
Med Universitat Wien-Allgemeines Krankenhaus Der Stadt Wien (AKH), Vienna
Cepon - Centro de Pesquisas Oncologicas, Florianópolis
Supera Oncologia, Santa Catarina
Icesp - Instituto Do Câncer Do Estado de São Paulo, São Paulo
Instituto Brasileiro de Controle Do Câncer, São Paulo
Hospital Albert Einstein, São Paulo
Mount Sinai Hospital, Toronto
Semmelweis Egyetem, Budapest
Orszagos Onkologiai Intezet, Budapest
Bekes Megyei Kozponti Korhaz, Gyula
Policlinico Universitario Agostino Gemelli, Rome
National Cancer Center Hospital, Chou-ku
Pan American Center For Oncology Trials, Llc, Rio Piedras
University Hospital Vall D'Hebron Institute of Oncology (VHIO), Barcelona
The Royal Marsden in Chelsea, London
The Royal Marsden in Sutton, Sutton, Surrey
Merck Sharp & Dohme LLC
INDUSTRY
Institut de Recherches Internationales Servier
OTHER
Servier Bio-Innovation LLC
INDUSTRY